Meeting
2019 ASCO Annual Meeting
EMERALD: A randomized, open label, phase III trial to evaluate the efficacy and safety of elacestrant (RAD1901) versus investigator’s choice (IC) of endocrine therapy (ET) for ER+/HER2- advanced breast cancer (BC) following CDK4/6 inhibitor (CDK4/6i) therapy.
Authors
Aditya Bardia
Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
Aditya Bardia , Philippe Georges Aftimos , Hai Jiang , Teeru Bihani , Alfred T Anderson-Villaluz , Maureen G. Conlan , Virginia G. Kaklamani
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT03778931
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS1104)
DOI
10.1200/JCO.2019.37.15_suppl.TPS1104
Abstract #
TPS1104
Poster Bd #
183a
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Lasofoxifene as a potential treatment for ER+ metastatic breast cancer.
First Author: Muriel Laine
Poster
2023 ASCO Annual Meeting
Comparative overall survival of patients in trials of CKD4/6 inhibitors in combination with endocrine therapy in advanced breast cancer.
First Author: Coralea Kappel
Poster
2022 ASCO Annual Meeting
Serena-1: Updated analyses from a phase 1 study (parts C/D) of the next-generation oral SERD camizestrant (AZD9833) in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer.
First Author: Mafalda Oliveira
Poster
2021 ASCO Annual Meeting
AMEERA-5: A randomized, double-blind phase III study of amcenestrant (SAR439859) + palbociclib versus letrozole + palbociclib for previously untreated ER+/HER2- advanced breast cancer.
First Author: Aditya Bardia